Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)

2009 ◽  
Vol 45 (18) ◽  
pp. 3189-3197 ◽  
Author(s):  
Alberto Fusi ◽  
Sandra Collette ◽  
Antonia Busse ◽  
Stefan Suciu ◽  
Anika Rietz ◽  
...  
Keyword(s):  
Distant Metastasis ◽  
Melanoma Cells ◽  
Stage Iii ◽  
Interferon Treatment ◽  
Free Survival ◽  
Distant Metastasis Free Survival ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Adjuvant Interferon

Photoacoustic detection of circulating melanoma cells as a predictor of metastasis in stage III patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21053-e21053
Author(s):  
John Andrew Viator ◽  
Martin Sanders ◽  
Ahmad A. Tarhini ◽  
Cindy Sander ◽  
Robert Hugh Edgar ◽  
...  
Keyword(s):  
Laser Light ◽  
Melanoma Cells ◽  
Ultrasonic Waves ◽  
Flow Cytometer ◽  
Disease State ◽  
Stage Iii ◽  
Blood Samples ◽  
Serial Blood ◽  
Melanoma Patients ◽  
Stage Iii Melanoma

e21053 Background: Circulating tumor cells have been correlated with disease state and distant metastatic spread in cancer patients. We postulated that enumerating circulating melanoma cells (CMCs) may predict the onset of distant metastasis in Stage III patients. We detected CMCs using our photoacoustic flow cytometer, in which we irradiated enriched blood samples with nanosecond pulsed laser light. While there is no effect on non-optically active leukocytes, absorption of laser light by pigmented melanoma cells resulted in robust ultrasonic waves that indicated CMCs in the sample. Methods: We tested 32 archived samples from 9 Stage III melanoma patients using our photoacoustic flow cytometer. Each patient had between 2 and 6 serial blood samples. We used a pulsed Nd:YAG laser to irradiate mononuclear cells in suspension and under flow. The number of CMCs detected after testing was recorded, indicating the time sequence of circulating tumor cell activity. Results: The numbers of CTCs for each sample is shown in the table below. The ultimate disease state, whether the patient became metastatic or not, was blinded to the investigators who performed the photoacoustic tests. One sample for patient 3 indicated 63 CMCs, though this test was known to be contaminated and had an unknown number of false detections. Conclusions: We found that patients who had a series of more than 4 CMCs were more likely to become metastatic than those patients who tested for 4 CMCs for fewer, indicating that a sequence of CMC detections in serial blood draws provides a potentially strong predictor of metastasis in Stage III melanoma patients warranting further investigation at this and lower stages of melanoma. We are developing a more rigorous model based on time series analysis of CMCs for prediction of metastasis. [Table: see text]

Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon

2002 ◽  
Vol 20 (19) ◽  
pp. 4032-4039 ◽  
Author(s):  
Begoña Mellado ◽  
Maria del Carmen Vela ◽  
Dolors Colomer ◽  
Lorena Gutierrez ◽  
Teresa Castel ◽  
...  
Keyword(s):  
Interferon Therapy ◽  
Surrogate Marker ◽  
Disease Free Survival ◽  
Melanoma Cells ◽  
Interferon Response ◽  
Interferon Treatment ◽  
Rt Pcr ◽  
Melanoma Patients ◽  
Adjuvant Interferon

PURPOSE: To evaluate the clinical significance of the detection of circulating melanoma cells in patients treated with adjuvant interferon and to determine their potential value as a marker of interferon response. PATIENTS AND METHODS: We prospectively analyzed 616 peripheral-blood samples from 120 melanoma patients with stage IIA (n = 33), IIB (n = 22), III (n = 50), or IV (surgically resected) (n = 15) disease receiving adjuvant interferon alfa-2b therapy. Tyrosinase mRNA was assayed by reverse transcriptase polymerase chain reaction (RT-PCR) as a marker of circulating melanoma cells before the start of interferon and every 2 to 3 months thereafter. RESULTS: With a median follow-up time of 32.3 months (range, 7.1 to 77.5 months), 47 patients (39.8%) relapsed and 31 (26%) died. During adjuvant interferon treatment, 76 patients (64%) had undetected circulating melanoma cells and 44 patients (36%) had a positive RT-PCR result in at least one sample. Actuarial 5-year disease-free survival was 62% in patients with persistently negative RT-PCR during interferon treatment and 38% for patients with positive RT-PCR during interferon (P = .02). Actuarial 5-year overall survival was 75% and 50%, respectively (P = .03). CONCLUSION: Patients with melanoma and tyrosinase mRNA detected in the blood during adjuvant interferon therapy had a worse prognosis compared with patients with undetected tyrosinase mRNA during treatment. Further investigation into the detection of circulating melanoma cells as a surrogate marker of response to adjuvant interferon therapy is warranted.

scholarly journals BRAF Mutation Correlates with Worse Local-regional Control Following Radiation Therapy in Patients with Stage III Melanoma

2021 ◽  
Author(s):  
Adam R Wolfe ◽  
Priyanka Chablani ◽  
Michael Siedow ◽  
Eric D Miller ◽  
Steve Walston ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Radiation Therapy ◽  
Lymph Node ◽  
Braf Mutation ◽  
Stage Iii ◽  
Free Survival ◽  
Regional Control ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Local Regional Control

Abstract Background In patients with stage III melanoma, the use of adjuvant radiation therapy (RT) after lymph node dissection (LND) may be currently considered in selected high-risk patients to improve local-regional control. Melanomas harbor BRAF mutations (BRAF+) in 40–50% of cases, the majority of which are on the V600E residue. This study sought to compare the clinical outcomes after RT between patients with BRAF + and BRAF- melanoma. Methods This was a retrospective review of 105 Stage III melanoma patients treated at our institution with LND followed by adjuvant RT from 2006–2019. BRAF mutational status was determined on the primary skin or nodal tissue samples from all patients. We compared characteristics of the BRAF + and BRAF- groups using Fisher’s exact test and Wilcoxon rank sum test and performed univariate and multivariate analysis using Kaplan-Meier estimates, log-rank tests, and Cox proportional hazards modeling with the clinical outcomes of local-regional control (LRC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Results Fifty-three (50%) patients harbored a BRAF mutation (92%, pV600E). BRAF + patients were younger and had primary tumors more commonly found in the trunk vs head and neck compared to BRAF- patients (p < 0.05). The 5 year local-regional control in the BRAF + patients was 60% compared to 81% in the BRAF- patients (HR 4.5, 95% CI 1.3–15.5, p = 0.02). There were no significant differences in 5-year DMFS, DFS, and OS rates between the two BRAF patient groups. The presence of 4 or more positive LNs remained a significant prognostic factor for LRC, DFS, and OS in multivariate analysis. Conclusions Stage III melanoma patients with BRAF mutation treated with adjuvant RT had > 4 times increased risk of loco-regional recurrence. These results could be useful for adjuvant RT consideration in lymph node positive melanoma patients and supports other data that BRAF mutation confers radiation resistance.

scholarly journals S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients

2009 ◽  
Vol 16 (12) ◽  
pp. 3455-3462 ◽  
Author(s):  
S. Kruijff ◽  
E. Bastiaannet ◽  
A. C. Muller Kobold ◽  
R. J. van Ginkel ◽  
A. J. H. Suurmeijer ◽  
...  
Keyword(s):  
Disease Free Survival ◽  
Stage Iii ◽  
Free Survival ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Disease Free

Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients

2015 ◽  
Vol 25 (4) ◽  
pp. 357-361 ◽  
Author(s):  
Ines Chevolet ◽  
Max Schreuer ◽  
Reinhart Speeckaert ◽  
Bart Neyns ◽  
Isabelle Hoorens ◽  
...  
Keyword(s):  
Stage Iii ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Immune Changes ◽  
Interferon Α2b ◽  
Adjuvant Interferon

Circulating melanoma cells and recurrence in stage III melanoma patients.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 9016-9016
Author(s):  
Anthony Lucci ◽  
Carolyn S. Hall ◽  
Mandar Karhade ◽  
Barbara A. Laubacher ◽  
Jessica Bowman Bauldry ◽  
...  
Keyword(s):  
Melanoma Cells ◽  
Stage Iii ◽  
Melanoma Patients ◽  
Stage Iii Melanoma
Sign in / Sign up

Export Citation Format

Share Document